04:21 AM EST, 02/25/2025 (MT Newswires) -- Myriad Genetics ( MYGN ) reported Q4 adjusted earnings late Monday of $0.03 per diluted share, down from $0.04 a year earlier.

Analysts polled by FactSet expected $0.03.

Revenue for the quarter that ended Dec. 31 was $210.6 million, up from $196.6 million a year earlier.

Analysts surveyed by FactSet expected $211.6 million.

The company expects a Q1 adjusted loss per share of $0.04 to $0.08 and 2025 adjusted EPS of $0.07 to $0.11, which it said is in line with its prior outlook. Analysts surveyed by FactSet expect a loss of $0.03 and earnings of $0.04, respectively.

The company expects Q1 revenue between $196 million and $204 million and continues to expect full-year revenue of $840 million to $860 million. Analysts polled by FactSet expect $206.6 million and $860.8 million, respectively.